ERBB2 and breast carcinoma: The clinical validation studies which were performed within a prospective-retrospective design showed that the test predicted distant metastasis in patients with primary ER-positive, HER2-negative breast cancer and provided significant prognostic information beyond standard parameters to assess the risk of metastasis.